| [1] |
Mitchell P, Liew G, Gopinath B, Wong TY. 2018. Age-related macular degeneration. |
| [2] |
Jeong YD, Park S, Kim MS, Hong SH, Aalruz H, et al. 2025. Global burden of vision impairment due to age-related macular degeneration, 1990–2021, with forecasts to 2050: a systematic analysis for the Global Burden of Disease Study 2021. |
| [3] |
Fleckenstein M, Keenan TDL, Guymer RH, Chakravarthy U, Schmitz-Valckenberg S, et al. 2021. Age-related macular degeneration. |
| [4] |
Khanani AM, Kotecha A, Chang A, Chen SJ, Chen Y, et al. 2024. TENAYA and LUCERNE two-year results from the phase 3 neovascular age-related macular degeneration trials of faricimab with treat-and-extend dosing in year 2. |
| [5] |
Korobelnik JF, Lanzetta P, Leal S, Holz FG, Clark WL, et al. 2026. Intravitreal aflibercept 8 Mg in neovascular age-related macular degeneration. |
| [6] |
Blazaki S, Blavakis E, Smoustopoulos G, Bontzos G, Stavrakakis A, et al. 2022. Progression of macular atrophy in patients receiving long-term anti-VEGF therapy for age-related macular degeneration: real-life data. |
| [7] |
Fleckenstein M, Schmitz-Valckenberg S, Chakravarthy U. 2024. Age-related macular degeneration: a review. |
| [8] |
Mangione CM. 2001. Development of the 25-list-item national eye institute visual function questionnaire. |
| [9] |
Suñer IJ, Kokame GT, Yu E, Ward J, Dolan C, et al. 2009. Responsiveness of NEI VFQ-25 to changes in visual acuity in neovascular AMD: validation studies from two phase 3 clinical trials. |
| [10] |
Lee H, Jo A, Kim HC. 2017. Three-dimensional analysis of morphologic changes and visual outcomes in neovascular age-related macular degeneration. |
| [11] |
Berni A, Oakley JD, Dolz-Marco R, Gallego-Pinazo R, Cimorosi F, et al. 2025. Topographical quantification of retinal fluid in type 3 MNV and associations with short-term visual outcomes. |
| [12] |
Dansingani KK, Tan ACS, Gilani F, Phasukkijwatana N, Novais E, et al. 2016. Subretinal hyperreflective material imaged with optical coherence tomography angiography. |
| [13] |
Shah VP, Shah SA, Mrejen S, Freund KB. 2014. Subretinal hyperreflective exudation associated with neovascular age-related macular degeneration. |
| [14] |
Willoughby AS, Ying GS, Toth CA, Maguire MG, Burns RE, et al. 2015. Subretinal hyperreflective material in the comparison of age-related macular degeneration treatments trials. |
| [15] |
Kawashima Y, Hata M, Oishi A, Ooto S, Yamashiro K, et al. 2017. Association of vascular versus avascular subretinal hyperreflective material with aflibercept response in age-related macular degeneration. |
| [16] |
Pu J, Zhuang X, Li M, Hao X, He G, et al. 2025. Early fluctuations of exudative lesions as predictors of two-year clinical outcomes in neovascular age-related macular degeneration. |
| [17] |
Pu J, Zhuang X, Li M, Zhang X, Ji Y, et al. 2026. Association between early lesion response and long-term anti-VEGF injection frequency in nAMD: a 2-year prospective study using 3D volumetric analysis. |
| [18] |
Pu J, Zhuang X, Li M, Zhang X, Su Y, et al. 2024. Analyzing formation and absorption of avascular subretinal hyperreflective material in nAMD from OCTA-based insights. |
| [19] |
Zhuang X, Pu J, Li M, Mi L, Zhang X, et al. 2024. Association between three-dimensional morphological features and functional indicators of neovascular age-related macular degeneration. |
| [20] |
Bressler NM, Chang TS, Suñer IJ, Fine JT, Dolan CM, et al. 2010. Vision-related function after ranibizumab treatment by better- or worse-seeing eye clinical trial results from MARINA and ANCHOR. |
| [21] |
Hirneiss C. 2014. The impact of a better-seeing eye and a worse-seeing eye on vision-related quality of life. |
| [22] |
Spaide RF, Jaffe GJ, Sarraf D, Freund KB, Sadda SR, et al. 2020. Consensus nomenclature for reporting neovascular age-related macular degeneration data consensus on neovascular age-related macular degeneration nomenclature study group. |
| [23] |
Ehlers JP, Lunasco LM, Yordi S, Cetin H, Le TK, et al. 2024. Compartmental exudative dynamics in neovascular age-related macular degeneration: volumetric outcomes and impact of volatility in a phase III clinical trial. |
| [24] |
Toth CA, Tai V, Pistilli M, Chiu SJ, Winter KP, et al. 2019. Distribution of OCT features within areas of macular atrophy or scar after 2 years of anti-VEGF treatment for neovascular AMD in CATT. |
| [25] |
Sadda S, Sarraf D, Khanani AM, Tadayoni R, Chang AA, et al. 2024. Comparative assessment of subretinal hyper-reflective material in patients treated with brolucizumab versus aflibercept in HAWK and HARRIER. |
| [26] |
Kumar JB, Stinnett S, Han JIL, Jaffe GJ. 2020. Correlation of subretinal hyperreflective material morphology and visual acuity in neovascular age-related macular degeneration. |
| [27] |
Strauss O. 2005. The retinal pigment epithelium in visual function. |
| [28] |
Curcio CA, Sloan KR, Kalina RE, Hendrickson AE. 1990. Human photoreceptor topography. |
| [29] |
Orr P, Rentz AM, Margolis MK, Revicki DA, Dolan CM, et al. 2011. Validation of the national eye institute visual function questionnaire-25 (NEI VFQ-25) in age-related macular degeneration. |
| [30] |
Roberts PK, Zotter S, Montuoro A, Pircher M, Baumann B, et al. 2019. Identification and quantification of the angiofibrotic switch in neovascular AMD. |
| [31] |
Llorente-González S, Hernandez M, González-Zamora J, Bilbao-Malavé V, Fernández-Robredo P, et al. 2022. The role of retinal fluid location in atrophy and fibrosis evolution of patients with neovascular age-related macular degeneration long-term treated in real world. |
| [32] |
Sivaprasad S, Tschosik E, Kapre A, Varma R, Bressler NM, et al. 2018. Reliability and construct validity of the NEI VFQ-25 in a subset of patients with geographic atrophy from the phase 2 mahalo study. |